GU Cancers Symp. 2014: mCRPC Treatment

REVIEW UroToday

Viewing 1-20 of 21 articles

GU Cancers Symposium 2014 - Increase in bone scan index during abiraterone treatment in relation to reduced survival in mCRPC patients - Poster

GU Cancers Symposium 2014 - Prospective evaluation of prescribing preferences by U.S.-based oncologists in the postdocetaxel mCRPC patient - Poster

GU Cancers Symposium 2014 - Evaluating the safety of abiraterone acetate and docetaxel administered in combination in patients with metastatic castration-resistant prostate cancer - Poster

GU Cancers Symposium 2014 - An indirect treatment comparison and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer post-chemotherapy - Poster

GU Cancers Symposium 2014 - Poster: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with mCRPC...

GU Cancers Symposium 2014 - Poster: Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study

GU Cancers Symposium 2014 - Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients - Poster

GU Cancers Symposium 2014 - Association of alkaline phosphatase with clinical outcomes in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Poster

GU Cancers Symposium 2014 - Model-based investigation of the interplay between abiraterone exposure, prostate-specific antigen kinetics, and overall survival in castration-resistant prostate cancer patients - Poster

GU Cancers Symposium 2014 - Best of journals - medical oncology - Session Highlights

GU Cancers Symposium 2014 - Population pharmacokinetic analysis of abiraterone acetate in healthy volunteers and chemotherapy-naive and chemotherapy-pretreated metastatic castration-resistant prostate cancer patients - Poster

GU Cancers Symposium 2014 - Response to androgen signaling-directed therapy after treatment with abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer: Post hoc analysis of study COU-AA-302 - Poster

GU Cancers Symposium 2014 - Does Gleason score predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer? An analysis of AA phase 3 trials - Poster

GU Cancers Symposium 2014 - Tumor board challenge - Session Highlights

GU Cancers Symposium 2014 - A decade in review: Prostate cancer - medical oncology - Session Highlights

GU Cancers Symposium 2014 - Session Highlights: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with mCRPC...

GU Cancers Symposium 2014 - Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)...

GU Cancers Symposium 2014 - Results of subset analyses on overall survival from study CA184-043: Ipilimumab (Ipi) versus placebo in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) - Session Highlights

GU Cancers Symposium 2014 - Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study - Session Highlights

GU Cancers Symposium 2014 - Enzalutamide decreases risk of death and delays progression in phase III trial of men with metastatic prostate cancer - Slide Presentation

1
2